drugset / Trial / NCT00280098
Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Evaluation of safety and efficacy of docetaxel in the treatment of advanced hormone refractory prostate cancer under the conditions of daily practise.
Timeline
- Start
- 2006-01
- Primary completion
- 2007-10
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 75 mg/m2 | — |